title: Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer.
abstract: OBJECTIVE
  This study evaluated the efficacy and safety of adjuvant intraperitoneal perfusion chemotherapy (IPC) in resectable gastric cancer through retrospective analysis.
  
  
  METHODS
  Three hundred and sixty T2-4bN0-3M0 resectable gastric cancer patients were included in this study. One hundred and eighty-four patients used systemic chemotherapy combined with IPC (IP+ group) and 176 systemic chemotherapy only (IP- group).
  
  
  RESULTS
  With a median of 49.9 months of follow-up, the 5-year overall survival in IP+ patients was significantly better than in IP- patients (60.4 vs. 42.9%; p = 0.001), and the average progression-free survival in IP+ patients was significantly longer than in IP- patients (60.5 vs. 46.2 months; p = 0.001). Relapse rates of peritoneal carcinomatosis, celiac lymph node and hepatic metastasis in the IP+ patients were significantly lower than in the IP- patients. Patients with curative resection, a histological type other than mucinous adenocarcinoma and signet ring cell carcinoma, low and undifferentiated tumor grade, lymph node metastasis, and T3 and T4a benefited from adjuvant IPC. The toxicities were the same except for more patients with leukopenia in the IP+ group (p = 0.001). The number of cycles of IPC and the time of IPC start after surgery had an impact on overall and disease-free survival.
  
  
  CONCLUSIONS
  Adjuvant IPC for resectable gastric cancer gave encouraging results and large multicenter prospective randomized controlled studies are warranted.
authors.affiliation: Department of Medical Oncology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Translational Cancer Medicine, No. 29 Xinquan Road, Fuzhou, Fujian, PR China.
authors.forename: Chunmei
authors.initials: C
authors.lastname: Shi
authors.forename: Baoyu
authors.initials: B
authors.lastname: Yang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Chen
authors.forename: Jianwei
authors.initials: J
authors.lastname: Yang
authors.forename: Nanfeng
authors.initials: N
authors.lastname: Fan
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000556:secondary*; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome